Following on from information provided to NICE by the company in May 2020 the appraisal of Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 2711 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 December 2022 | Discontinued. Following on from information provided to NICE by the company in May 2020 the appraisal of Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 November 2020 | The Department for Health and Social Care has asked NICE to carry out an appraisal of pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer ID2711. For information, the company have announced that pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer ID2711 did not meet its primary endpoint and therefore they will no longer be pursuing a marketing authorisation application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 14 May 2020 | Suspended. Topic has been suspended |
| 14 May 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes. |
| 10 January 2020 | In progress. Referred October 28 2019 |
For further information on our processes and methods, please see our CHTE processes and methods manual